Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Antiarrhythmic Agents II: Therapeutic Considerations
Dean T. Mason
, A. N. DeMaria
, E. A. Aterdam
, R. Zelis
, R. A. Massumi
Department of Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
4
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Antiarrhythmic Agents II: Therapeutic Considerations'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Antiarrhythmic Agent
100%
Propranolol
75%
Lidocaine
50%
Myocardium
50%
Quinidine
50%
Tachycardia
50%
Procainamide
50%
Electric Shock
50%
Sodium Ion
25%
Cell Membrane
25%
Cardiac Dysrhythmia
25%
Calcium Ion
25%
Therapeutic Modality
25%
Ventricle of Heart
25%
Potassium Ion
25%
Arrhythmia
25%
Rhythm
25%
Inotropism
25%
Heart Muscle Conduction Disturbance
25%
Vascular Resistance
25%
Ventricular Tachycardia
25%
Refractory Period
25%
Sinus Rhythm
25%
Clinical Management
25%
Tachyarrhythmia
25%
Adverse Drug Reaction
25%
Hyperkalemia
25%
Supraventricular Tachycardia
25%
Pathognomonic
25%
Bretylium
25%
Atrioventricular Node
25%
Heart Muscle Contractility
25%
Pharmacodynamics
25%
Disease
25%
Third-Degree Atrioventricular Block
25%
Atrium
25%
Vagus Nerve Stimulation
25%
Diseases
25%
Myocardial Disease
25%
Potassium Ion
25%
Keyphrases
Antiarrhythmic Agents
100%
Therapeutic Considerations
100%
Ventricular Arrhythmia
42%
Propranolol
42%
Digitalis Toxicity
42%
Potassium
28%
Myocardium
28%
Pacemaker
28%
Quinidine
28%
Direct Current
28%
Tachyarrhythmia
28%
Glycosides
28%
Phenytoin
28%
Procainamide
28%
Cell Membrane
14%
Na +
14%
Mechanism of Action
14%
Vasodilator
14%
Arrhythmia
14%
Clinical Management
14%
Ventricle
14%
Atropine
14%
Pharmacodynamics
14%
Conduction Disturbances
14%
Contractile Properties
14%
Peripheral Vascular Resistance
14%
Cardiac Cells
14%
Therapeutic Modalities
14%
Cardiac Contractility
14%
Hyperkalemia
14%
Clinical Conditions
14%
Electrophysiologic
14%
Electrophysiological Properties
14%
Antiarrhythmic Drugs
14%
Normal Sinus Rhythm
14%
Ventricular Pacing
14%
Atrial Pacing
14%
Onset of Action
14%
Supraventricular Arrhythmia
14%
Action Effects
14%
Duration of Action
14%
Electrophysiological Effects
14%
Adverse Drug Reaction
14%
Ventricular Rate
14%
Ca++
14%
Atrioventricular Node
14%
Refractory Period
14%
Atrium
14%
Pathognomonic
14%
Complete Heart Block
14%
Automaticity
14%
Serum Potassium
14%
Vagus Nerve Stimulation
14%
Inotropic Action
14%
Diphenylhydantoin
14%
Conduction Velocity
14%
Electrophysiological Changes
14%
Transmembrane Flux
14%
Pharmacology, Toxicology and Pharmaceutical Science
Antiarrhythmic Agent
100%
Propranolol
75%
Isotopes of Potassium
75%
Phenytoin
75%
Digoxin Toxicity
75%
Heart Arrhythmia
50%
Quinidine
50%
Lidocaine
50%
Glycoside
50%
Procainamide
50%
Pharmacodynamics
25%
Bretylium
25%
Calcium Ion
25%
Potassium Ion
25%
Sodium Ion
25%
Adverse Drug Reaction
25%
Hyperkalemia
25%
Heart Ventricle Tachycardia
25%
Tachycardia
25%
Supraventricular Tachycardia
25%
Complete Heart Block
25%
Myocardial Disease
25%
Diseases
25%
Heart Muscle Conduction Disturbance
25%
Veterinary Science and Veterinary Medicine
Antiarrhythmic Agent
100%
Propranolol
75%
Cardiac Dysrhythmia
50%
Lidocaine
50%
Contractility
25%
Vascular Resistance
25%
Ventricular Tachycardia
25%
Supraventricular Tachycardia
25%
Tachyarrhythmia
25%
Tachycardia
25%
Third-Degree Atrioventricular Block
25%
Calcium Ion
25%
Potassium Blood Level
25%